OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Borchmann Discusses the Updated Analysis of JULIET in DLBCL

June 21st 2018

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses the updated analysis of the JULIET trial in patients with diffuse large B-cell lymphoma (DLBCL).

Dr. Husain on Plasma-Based Testing in Lung Cancer

June 20th 2018

Hatim Husain, MD, assistant professor of Medicine, Moores Cancer Center, University of California, San Diego, discusses plasma-based testing in lung cancer.

Dr. Rini Discusses Atezolizumab Plus Bevacizumab in RCC

June 20th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Dr. Davids Discusses Duvelisib in Relapsed/Refractory CLL

June 20th 2018

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib in relapsed/refractory chronic lymphocytic leukemia.

Dr. Mitri on Neratinib and Pertuzumab in HER2-Amplified Breast Cancer

June 19th 2018

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the use of neratinib (Nerlynx) and pertuzumab (Perjeta) in patients with HER2-amplified breast cancer.

Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer

June 19th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.

Dr. Wirth on the Use of Lenvatinib in Hypertensive Patients With Thyroid Cancer

June 18th 2018

Lori J. Wirth, MD, associate professor, Medicine, Harvard Medical School, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, discusses the use of lenvatinib in hypertensive patients with thyroid cancer.

Dr. Singh on the Use of Chemotherapy in Patients With Uterine Leiomyosarcomas

June 18th 2018

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the use of chemotherapy in patients with uterine leiomyosarcomas.

Dr. Bekaii-Saab on Immunotherapy in Colorectal Cancer

June 18th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Dr. Savin on the Evolution of Biosimilars

June 16th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.

Dr. Giri on Genes that Carry a Risk for Prostate Cancer

June 16th 2018

Veda Giri, MD, associate professor, Thomas Jefferson University Hospital, discusses genes that are associated with a risk of developing prostate cancer.

Dr. McCann on Prognosis for Patients With HER2-Positive Breast Cancer

June 16th 2018

Kelly McCann, MD, PhD, a medical oncologist in the Breast Cancer Research Group at the University of California, Los Angeles, discusses the current prognosis for patients with HER2-positive breast cancer.

Dr. Zibelman on Managing Immune-Related Adverse Events

June 16th 2018

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).

Dr. Borghaei Discusses the Results of CheckMate-227 in NSCLC

June 14th 2018

Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the results of the CheckMate-227 trial in non–small cell lung cancer.

Dr. Drake Discusses the CARMENA Trial in Metastatic RCC

June 14th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the CARMENA trial in metastatic renal cell carcinoma (mRCC).

Dr. McBride Discusses Financial Toxicity in Oncology

June 14th 2018

Ali McBride, PharmD, MS, BCOP, Clinical Coordinator of Hematology/Oncology, The University of Arizona Cancer Center, and President-Elect of the Association of Community Cancer Centers.

Dr. Biran on Patient-Reported Outcomes Following Transplant in Multiple Myeloma

June 14th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses patient-reported outcomes following autologous stem cell transplantation in multiple myeloma.

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.

Dr. Tewari on Trial With Cemiplimab in Recurrent or Metastatic Cervical Cancer

June 14th 2018

Krishnansu Tewari, MD, associate professor, Division of Gynecologic Oncology, University of California, Irvine, discusses the GOG 3016/ENGOT-cx9 trial in patients with recurrent or metastatic cervical cancer.

Dr. Goy on the Approval of Pembrolizumab in PMBCL

June 13th 2018

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) for patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL).